Shares surged as Connect Biopharma confirmed it has satisfied Nasdaq's minimum $1.00 bid-price rule, eliminating the threat of delisting that had dogged the stock since March 2025. The stock jumped 17% to $2.75 in pre-market trading, extending a run that has seen it climb from penny-stock territory. For a company with a roughly $90 million market cap and no marketed products, staying listed is table-stakes survival — but the real question is whether the clinical story behind the rally can sustain it.
The Delisting Cloud Is Gone — For Now
Connect received a Nasdaq deficiency notice in March 2025 after its shares closed below $1.00 for 30 consecutive business days.
The company has now regained compliance, with Nasdaq confirming its shares held above $1.00 for at least 10 straight trading days. Removal of the delisting overhang matters because many institutional funds are barred from holding stocks under regulatory threat — clearing this hurdle reopens the door to a broader investor base.
A Drug Pipeline That's Generating Real Momentum The stock's recovery isn't just procedural. In March, Connect reported positive Phase 1 results for an intravenous version of its lead drug — a biologic designed to block inflammation in asthma and COPD — showing rapid, clinically meaningful lung-function improvement within 15 minutes.
Separately, Phase 3 data in a severe skin condition showed near-maximal responses in roughly 90% of patients over 52 weeks.
The company is targeting the emergency asthma and COPD market in the U.S., a space with no approved biologic treatments — a potential first-mover advantage if trials succeed.
Cash Runway Buys Time, But the Clock Is Ticking
A $20.2 million private placement at $3.25 per share closed in Q1, leaving the company with $46.0 million in cash and a runway into the second half of 2027.
The FY2025 net loss was $55.5 million on $37.8 million in R&D spending and just $64,000 in revenue. At that burn rate, another capital raise is virtually certain before any drug could reach the market.
Milestones Will Make or Break the Stock
Phase 2 trial data for acute asthma and COPD are expected mid-2026 , and Connect stands to collect up to $110 million in milestone payments from its Chinese partner Simcere if the drug hits regulatory and commercial targets. Those catalysts could justify a far higher valuation — or, if data disappoint, send the stock right back toward the danger zone.